Neurostimulation Devices Market Revenue is Predicted to Surpass a Valuation of US$ 36.5 billion by 2032, States by Market.us
May 24, 2023 06:57 ET
|
Market.Us
New York, May 24, 2023 (GLOBE NEWSWIRE) -- The Neurostimulation Devices Market stood at US$ 11.1 billion in 2022 and the global market is projected to reach US$ 36.5 billion by 2032. The global...
NeuroOne® to Report Second Quarter Fiscal Year 2023 Financial Results and Provide a Corporate Update on May 11
May 11, 2023 12:17 ET
|
NeuroOne Medical Technologies Corp
EDEN PRAIRIE, Minn., May 11, 2023 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) ("NeuroOne" or the "Company"), a medical technology company focused on improving...
Exosome Technologies Market Value to Reach USD 343.5 Mn by 2031, rising at a CAGR of 24.8%: TMR Study
May 05, 2023 08:30 ET
|
Transparency Market Research
Wilmington, Delaware, United States, May 05, 2023 (GLOBE NEWSWIRE) -- The global exosome technologies market was valued at USD 47.3 Mn in 2022 and is projected to exceed USD 343.5 Mn by 2031. ...
High Intensity Focused Ultrasound (HIFU) Market to Surpass US$ 182.9 Million by 2030, Says Coherent Market Insights (CMI)
March 09, 2023 09:00 ET
|
CMI
Burlingame, March 09, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, Global High-Intensity Focused Ultrasound (HIFU) Market is estimated to be valued at US$ 112.7 million in 2023...
Dystonia Drugs Market Is Expected to Reach $1378.67 Million by 2031: Says AMR
March 08, 2023 20:30 ET
|
Allied Market Research
Portland, OR, March 08, 2023 (GLOBE NEWSWIRE) -- According to the report published by Allied Market Research, the global dystonia drugs market was valued at $806.67 million in 2021, and is projected...
ResolutionRx Ltd, a wholly owned subsidiary of RespireRx Pharmaceuticals Inc. Enters into LOI and Term Sheet with Radium Capital for the financing of anticipated Research and Development Credits
February 01, 2023 08:30 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
RespireRx Pharmaceuticals Inc. Enters a Collaboration With National Institute for Neurological Disorders and Stroke to Advance its Lead GABAkine Toward Clinical Development
December 05, 2022 08:30 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Pacemakers Market to Gain $10.9 Bn Revenue With 8.1% CAGR by 2027 | The Insight Partners
November 15, 2022 08:16 ET
|
The Insight Partners
New York, Nov. 15, 2022 (GLOBE NEWSWIRE) -- According to The Insight Partners new market research study titled ‘Pacemakers Market Size, Share, Growth, Global Analysis and Forecasts by Product Type,...
RespireRx Pharmaceuticals Inc. Announces that Sleep Review has discussed the RespireRx Dronabinol Obstructive Sleep Apnea (OSA) Program in its June 13, 2022 Edition
August 08, 2022 08:00 ET
|
RespireRX Pharmaceuticals Inc.
Glen Rock, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQ:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
Global Functional Electrical Stimulation Market to Grow with a CAGR of ~8.5% During 2022-2031; Market to Grow on Account of the Increasing Prevalence of Paralysis and Technological Advancement in the Healthcare Sector
June 22, 2022 08:23 ET
|
Research Nester
New York, June 22, 2022 (GLOBE NEWSWIRE) -- As Per World Health Organization, every year, between 250000 to 500000 persons suffer a spinal cord injury in the world. Functional electrical stimulation...